8-K: Citius Oncology Reports Positive LYMPHIR Phase 1 DLBCL Data

Citius Oncology announced positive topline safety and efficacy results from a Phase 1 trial of LYMPHIR in high-risk relapsed or refractory diffuse large B-cell lymphoma patients.

Summary

• Positive topline safety and efficacy results were announced from an investigator-initiated Phase 1 trial evaluating LYMPHIR (E7777) administered prior to commercial CD19-directed CAR-T therapy in patients with high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
• The overall response rate (ORR) was 86% at one month, including 57% complete responses (CR) and 29% partial responses (PR).
• One-year progression-free survival (PFS) was 77% (95% CI: 43-92%), and one-year overall survival (OS) was 84% (95% CI: 49-96%).
• LYMPHIR was well-tolerated, with no dose-limiting toxicities (DLTs) observed across the 5, 7, or 9 µg/kg dose levels.
• Effective depletion of circulating regulatory T-cells (Tregs) was observed in all but one patient, with a median reduction of 24 Tregs/L.
• Reported adverse events included manageable Grade 1-2 capillary leak syndrome, fever, and transient liver enzyme elevations; Grade 3 cytopenias were consistent with expected lymphodepletion.
• CAR-T related cytokine release syndrome (CRS) occurred in 43% of patients (all Grade 1/2), and immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 21% (primarily low grade).

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development given the strong efficacy and safety signals in a challenging patient population, suggesting potential to enhance established CAR-T therapies and expand LYMPHIR's market.

Positives

• High overall response rate (ORR) of 86% at one month in a high-risk DLBCL population, demonstrating significant anti-tumor activity.
• Strong complete response (CR) rate of 57% and partial response (PR) rate of 29%, indicating deep and meaningful responses.
• Encouraging one-year progression-free survival (PFS) of 77% and one-year overall survival (OS) of 84% for a difficult-to-treat patient group.
• LYMPHIR was well-tolerated with no dose-limiting toxicities observed up to 9 µg/kg, suggesting a favorable safety profile in this combination regimen.
• Effective depletion of circulating regulatory T-cells (Tregs) was achieved in nearly all patients, supporting the immunomodulatory mechanism of action.
• Low incidence and severity of CAR-T related adverse events, with all cytokine release syndrome (CRS) being Grade 1/2 and immune effector cell-associated neurotoxicity syndrome (ICANS) primarily low grade.

Risks

• Early-stage clinical data may not be predictive of results from larger or later-stage studies.
• The company needs substantial additional funds and its ability to raise additional money to fund operations for at least the next 12 months as a going concern is a risk.
• Ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream is not guaranteed.
• The estimated markets for LYMPHIR and product candidates and their acceptance by any market are subject to uncertainty.
• Ability to secure strategic partnerships and expand international access to LYMPHIR is a risk.
• Maintaining Nasdaq's continued listing standards is a requirement.
• Physician and patient acceptance of LYMPHIR in a competitive treatment landscape is crucial.
• Reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations poses risks.
• Ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply are ongoing challenges.
• Post-marketing requirements and ongoing regulatory compliance related to LYMPHIR are necessary.
• Ability to procure cGMP commercial-scale supply is essential for commercialization.
• Patent and intellectual property matters, government regulation, and the impact of any future public health risks could negatively affect the business.
• LYMPHIR carries a Boxed Warning for Capillary Leak Syndrome (CLS), including life-threatening or fatal reactions, which occurred in 27% of patients in pooled clinical trials (8% Grade 3, 0.8% fatal).
• Serious visual impairment, including changes in visual acuity and color vision, occurred in 9% of patients in pooled trials (8% Grade 1, 1% Grade 2).
• Serious infusion-related reactions were reported in 69% of patients in pooled trials (3.4% Grade 3).
• Hepatotoxicity can occur, with elevated ALT in 70% of patients (22% Grade 3) and elevated AST in 64% (9% Grade 3) in pooled trials.
• Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman, requiring effective contraception for females of reproductive potential.
• There are no data on LYMPHIR in human milk, and women are advised not to breastfeed during treatment and for 7 days after the last dose due to potential serious adverse reactions in breastfed children.
• Based on findings in rats, male fertility may be compromised by treatment with LYMPHIR, with unknown reversibility.

Future Outlook

The positive Phase 1 data supports Citius Oncology's broader strategy of exploring LYMPHIR's modulatory effect on regulatory T-cells (Tregs) in combination with other approved therapies to potentially enhance the body's own immune system to fight cancerous tumors. This data also sets the stage for a larger study to assess LYMPHIR's potential to enhance CAR-T efficacy through longer duration of use.

Management Comments

• "These positive data support our broader strategy of exploring LYMPHIRs modulatory effect on Tregs in combination with other approved therapies to potentially enhance the bodys own immune system to fight cancerous tumors." Dr. Myron Czuczman, Executive Vice President and Chief Medical Officer of Citius Oncology and Citius Pharma.
• "In this high-risk population, LYMPHIR showed a favorable safety profile and promising pharmacodynamic effects when administered prior to CAR-T therapies. This data sets the stage for a larger study to assess its potential to enhance CAR-T efficacy through longer duration of LYMPHIR use." Dr. Veronika Bachanova, Principal Investigator and Professor of Medicine at the University of Minnesota.

Industry Context

StockSavvy.ai notes that the positive Phase 1 results for LYMPHIR in combination with CAR-T therapy for high-risk DLBCL represent a significant development in the competitive oncology landscape. By targeting regulatory T-cells (Tregs) to augment lymphodepletion, Citius Oncology is exploring an immunomodulatory strategy that could enhance the effectiveness of existing FDA-approved CAR-T products like Yescarta (Kite Pharma/Gilead Sciences), Breyanzi (Bristol Myers Squibb), and Kymriah (Novartis) in a patient population with poor prognoses. This approach addresses a critical unmet need for improving outcomes in relapsed or refractory DLBCL, a common and aggressive non-Hodgkin lymphoma subtype where up to 40% of patients experience relapse.

Comparison to Industry Standards

• The study utilized FDA-approved commercial CAR-T products: axicabtagene ciloleucel (Yescarta; Kite Pharma/Gilead Sciences), lisocabtagene maraleucel (Breyanzi; Bristol Myers Squibb), or tisagenlecleucel (Kymriah; Novartis).
• The reported 86% ORR, 57% CR, 77% one-year PFS, and 84% one-year OS in a high-risk DLBCL population (including double/triple hit genetics, primary refractory disease, and extranodal involvement) are highly encouraging. While direct comparative efficacy conclusions cannot be drawn from a Phase 1 study, these rates appear favorable, especially considering the challenging patient cohort, when compared to historical data for CAR-T therapies alone in similar high-risk settings. For instance, real-world data for CAR-T therapies in relapsed/refractory DLBCL often show lower response rates and durability in very high-risk or heavily pre-treated populations.
• The favorable safety profile of LYMPHIR in this combination, with no DLTs and manageable Grade 1-2 adverse events, is a positive differentiator, as CAR-T therapies are known for significant toxicities like CRS and ICANS.

Stakeholder Impact

• Shareholders: Positive clinical trial results could lead to increased investor confidence and potential share price appreciation due to expanded market potential and de-risking of the asset.
• Patients: Offers a promising new immunomodulatory strategy to improve outcomes for high-risk relapsed or refractory DLBCL patients who currently have limited and often insufficient treatment options.
• Healthcare Providers: Provides a potential new therapeutic approach to enhance CAR-T therapy effectiveness, offering a valuable tool for managing challenging DLBCL cases.
• Competitors: May face increased competition or pressure to develop similar combination strategies if LYMPHIR's approach proves successful in larger trials, potentially shifting treatment paradigms in DLBCL.

Next Steps

• Conduct a larger study to assess LYMPHIR's potential to enhance CAR-T efficacy through longer duration of LYMPHIR use.
• Continue exploring LYMPHIR's modulatory effect on Tregs in combination with other approved therapies to potentially enhance the body's own immune system to fight cancerous tumors.

Key Dates

Recommendation

The positive topline Phase 1 data for LYMPHIR in combination with CAR-T therapy for high-risk DLBCL is a significant de-risking event and indicates a substantial market opportunity. The high overall response rate, complete response rate, and impressive one-year progression-free and overall survival rates in a difficult-to-treat population, coupled with a favorable safety profile, suggest a strong potential for LYMPHIR to enhance the efficacy of existing CAR-T treatments. This could position Citius Oncology for future larger studies and potential market expansion beyond its current CTCL indication, making it an attractive investment for long-term growth.

Keywords

Citius Oncology, CTOR, LYMPHIR, E7777, denileukin diftitox-cxdl, CAR-T therapy, DLBCL, diffuse large B-cell lymphoma, Phase 1 trial, oncology, biopharmaceutical, relapsed refractory, T-cell lymphoma, CTCL, clinical trial, immunotherapy, regulatory T-cells, Tregs, cancer treatment, Nasdaq